FINWIRES · TerminalLIVE
FINWIRES

China's Drug Regulator Accepts Marketing Application of Humanwell's Subsidiary for Landiolol Hydrochloride

By

China's National Medical Products Administration accepted the marketing application of Humanwell Healthcare's (SHA:600079) subsidiary, Yichang Humanwell Pharmaceutical, for landiolol hydrochloride for injection, according to a Shanghai bourse filing on Thursday.

The drug is used for the treatment of tachyarrhythmias in patients with heart failure or during surgery.

The pharmaceutical company invested 9.5 million yuan into the research and development of the drug.

Related Articles

Asia

Market Chatter: Malaysia Ensures Stable Gas Supply Despite Global Shortage

Malaysia's gas supply remains stable, with most electricity generation still backed by domestic sources, while the government continues to monitor the energy sector amid global uncertainties, The Star reported Thursday, citing Science, Technology and Innovation Minister Datuk Chang Lih Kang.Around 80% of the country's power generation is supported by local resources, limiting exposure to external supply risks. Currently, the supply conditions are comfortable and do not raise any immediate concerns, according to the report.Separately, Gas Malaysia (KLSE:GASMSIA) chief executive Azli Mohamed said the industry is not experiencing any gas shortages. He noted that supplies are primarily sourced from domestic fields and Australia, with only minimal dependence on the Middle East. However, he cautioned thathigher logistics costs and supply chain disruptions could still emerge, The Star said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^KLSE$KLSE:GASMSIA
Asia

Hillstone Networks' 267 Million Yuan Convertible Bonds Downgraded

Lianhe Credit Rating downgraded Hillstone Networks' (SHA:688030) convertible bonds worth 267.4 million yuan to A- from A after reviewing the company's operating conditions and the industry environment, according to a Shanghai bourse filing on Thursday.The downgrade was posted in the rating firm's report published May 28.The rating outlook of the six-year bond, which will mature March 21, 2028, remains negative.The Chinese information technology company's shares dropped 4% at the close.

$SHA:688030
Asia

Ramssol Unit to Buy Stakes in Two Firms Worth MYR14 Million

Ramssol Group (KLSE:RAMSSOL) unit Rams Fintech proposed to acquire stakes in Innio and Agensi Pekerjaan Innio for a combined 14.4 million ringgit.The deal includes a 3.6 million ringgit payment in cash and the issuance of 15.4 million new Ramssol shares at 0.70 ringgit each.The businesses are involved in manpower outsourcing, recruitment, and AI-driven job-matching services across Southeast Asia.Post-acquisition, Innio will become a 60% unit, while Agensi Pekerjaan Innio will be owned 49% by the company.The deal is expected to be completed by the third quarter, subject to regulatory and other approvals, it added.

$KLSE:RAMSSOL